The FDA's shortage-based permission for bulk compounded semaglutide and tirzepatide is ending, and with it, the legal basis that let telehealth platforms supply hundreds of thousands of patients through 503B outsourcing facilities. This did not happen because of a single new rule. It happened because five separate pieces of federal law, some nearly a century old, work together to define what "legal" compounded GLP-1 access even means. Understanding those pieces helps explain what is closing and what still remains open for patients.
That standard, set by the Federal Food, Drug, and Cosmetic Act of 1938, requires a drug to go through premarket review before it can carry FDA approval. Compounded medications, by design, sit outside that process. A compounding pharmacy or outsourcing facility does not submit its version of semaglutide or tirzepatide for the same review that Ozempic, Wegovy, or Zepbound underwent. This is not a loophole or an oversight. It is the structural reason compounded GLP-1s were never approved products in the first place, even during the years when they were legal to dispense.
That classification came from the Durham-Humphrey Amendment of 1951, which split drugs into prescription and over-the-counter categories and required a licensed practitioner's involvement for the former. That framework is what makes patient-specific compounding possible at all under section 503A: a pharmacist can only prepare an individualized formulation in response to a valid prescription tied to a real patient's documented need. Without that 1951 line between prescription and non-prescription drugs, there would be no legal foundation for the 503A pathway that remains open even as the 503B bulk route closes. It is a narrower path than bulk compounding, built one prescription at a time, but it rests on law that predates the GLP-1 shortage by more than seventy years.
That deal, created by the Omnibus Budget Reconciliation Act of 1990, set up the Medicaid Drug Rebate Program, in which manufacturers agree to rebate a portion of the price back to Medicaid in exchange for their drugs being covered. That arrangement matters here because it shapes what happens to patients who lose access to compounded versions. Coverage for the FDA-approved products, the ones Medicaid rebate agreements apply to, does not automatically extend to compounded alternatives, since compounded drugs sit outside the approval and rebate structure altogether. For patients relying on Medicaid, the end of compounded access does not open a new coverage door. It shifts the question back to whether the approved product itself is covered and affordable under the existing rebate arrangement.
That law, the Veterans Health Care Act of 1992, created the 340B Drug Pricing Program, which requires manufacturers to sell outpatient drugs at a discount to certain safety-net providers and covered entities. Some patients losing access to compounded GLP-1s may find that a 340B-eligible clinic or health center offers a path to the approved product at a lower price than they would otherwise pay. This is not a universal fix, since 340B pricing depends on where a patient gets care and whether that provider qualifies as a covered entity. Still, for patients facing the closing compounded market, it is one of the few federally established discount mechanisms worth asking about.
That authority, granted under the FDA Safety and Innovation Act of 2012, gave the FDA formal power to track and declare drug shortages, and it is the same authority that opened the 503B bulk-compounding door for semaglutide and tirzepatide in 2022. The law works in both directions: it can open access when a shortage is declared, and it withdraws that access once the shortage is resolved. That is exactly what is happening now, as the FDA moves to exclude these drugs from the 503B bulks list because the clinical justification tied to the shortage no longer exists. The 2012 law was never a permanent grant of compounding rights. It was always a shortage-contingent one, and the current proposed rule is that contingency working exactly as written.
None of these laws were written with GLP-1 drugs in mind, yet together they explain both why compounded access existed and why it is ending. If you currently rely on a compounded semaglutide or tirzepatide product, the practical step is to talk with your prescriber now about what an FDA-approved alternative would look like for you, including whether a 340B-eligible provider or your existing coverage changes that calculation. Waiting until the rule is finalized and the supply disappears leaves fewer options and less time to sort out coverage or dosing. This is a legal and supply question, not a medical one, but it is worth planning for before the shortage-era arrangement fully closes.
Key details
The 1938 law's approval standard is why compounded GLP-1s aren't FDA-approved.
A 1951 amendment's prescription classification underlies the 503A patient pathway.
Medicaid's 1990 rebate deal shapes coverage options if compounding access ends.
Veterans law from 1992 created the 340B discount path some patients may rely on.
FDASIA's 2012 shortage authority is the mechanism now closing GLP-1 compounding.